The Link Between Gut Microbiome, Inflammation, and Autoimmune Diseases

Introduction: The Gut as the Center of Immunity

The human gut is not merely a digestive organ, but a complex ecosystem populated by trillions of microorganisms known as the gut microbiome. This microbial population plays a critical role in maintaining health by participating in nutrient metabolism, vitamin synthesis, and, most importantly, modulating the immune system. Disruption of the microbiome balance, or dysbiosis, is increasingly linked to the development of various diseases, including inflammatory and autoimmune conditions that often underlie rheumatic diseases.

The interaction between the gut microbiome and the immune system is continuous. Microbes and their metabolites can both suppress and stimulate inflammatory responses, influencing the functioning of immune cells both locally in the gut and systemically throughout the body. Understanding this complex connection opens new perspectives for the diagnosis and treatment of many chronic conditions.

Dysbiosis and Autoimmune Diseases: The Example of Multiple Sclerosis

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system in which the immune system mistakenly attacks the myelin sheath of nerve fibers. Research shows that the gut microbiome plays a significant role in the pathogenesis of MS through its influence on immune regulation and the gut-brain axis [1].

In one study, it was found that patients with relapsing-remitting multiple sclerosis (RRMS) have a significantly reduced microbial richness and diversity of the gut microbiota compared to healthy individuals. This manifested as a decrease in the number of observed taxonomic units (ASVs) and a lower Shannon index. Although the composition was similar at the bacterial phylum level (Firmicutes and Bacteroidota), beta-diversity analysis revealed substantial differences between groups, indicating a unique microbial profile in patients with RRMS [1]. These changes in microbiome composition may contribute to the development of inflammation and autoimmune reactions characteristic of MS.

Microbiome, Inflammation, and Systemic Diseases

An imbalance in the gut microbiome can promote systemic inflammation, which is a key factor in many chronic diseases. The gut microbiota produces membrane vesicles (MVs) that play an important role in immunomodulation and the maintenance of the intestinal microecosystem. These MVs can carry various molecules, influencing immune cells and promoting either inflammation or its suppression [2].

For example, in chronic kidney disease (CKD), which is often accompanied by systemic inflammation, alterations in the gut microbiota are observed. Research shows that patients with CKD combined with acute myocardial infarction (AMI) exhibit specific microbial and metabolic characteristics. These changes correlate with an increase in the number of immune cells, highlighting the role of the gut in systemic inflammatory processes [3]. Understanding the mechanisms by which MVs and other microbial factors influence immunity may have great clinical significance for the diagnosis and treatment of such conditions [2].

The Role of Metabolites and Specific Bacteria

Gut bacteria produce numerous metabolites that can have both beneficial and harmful effects on the body. For instance, short-chain fatty acids (SCFAs) are known for their anti-inflammatory properties. However, not all bacteria are beneficial. Studies on irritable bowel syndrome (IBS) have shown that while overall microbial diversity may not differ significantly, patients with IBS exhibit an increased abundance of bacteria such as Christensenellaceae R-7 group, Clostridium sensu stricto 1, and Negativibacillus [5]. These changes in microbiome composition functionally interact with systemic metabolic disorders, indicating their role in the pathophysiology of IBS [5].

On the other hand, certain bacteria and their metabolites demonstrate protective properties. For example, metabolites derived from the bacterium Komagataeibacter rhaeticus SLAM-JS1B showed the ability to reduce inflammation (by decreasing the expression of pro-inflammatory cytokines) and improve intestinal barrier integrity in studies on mice with high-fat diet-induced obesity [7]. This highlights the potential of targeted interventions on the microbiome to modulate inflammatory processes.

The Gut-Brain Axis: Connection to Neurological Conditions

The influence of the gut microbiome extends beyond the immune system to the central nervous system via the so-called gut-brain axis. This interaction is particularly noticeable in diseases such as Parkinson's disease (PD). Studies have identified causal links between specific gut microorganisms and the risk of developing PD, as well as constipation, which often precedes neurological symptoms [4].

For example, a genetically predicted higher level of Bifidobacterium correlated with a decreased risk of PD [8]. Conversely, high levels of certain SCFA-producing bacteria, such as Lachnospiraceae UCG010, Ruminococcaceae UCG002, Clostridium sensu stricto 1, and Eubacterium hallii group, were associated with an increased risk of PD [8]. These findings indicate the complex role of various microbial groups in the development of neurodegenerative diseases.

Furthermore, irritable bowel syndrome (IBS) and generalized anxiety disorder (GAD) share common pathogenetic mechanisms related to immune cells, plasma metabolites, inflammatory factors, and the gut microbiota. Research has shown causal links between various gut microbe taxa and the development of IBS/GAD, as well as between IBS and GAD themselves [6]. For example, the bacterium Bilophila contributes to the development of GAD [6].

Prospects: Targeted Microbiome Therapy

A deep understanding of the connection between the gut microbiome, inflammation, and autoimmune diseases opens new horizons for therapeutic interventions. Targeted modification of microbiome composition and function could become an effective strategy for the prevention and treatment of a wide range of conditions, including those related to rheumatic diseases.

Potential approaches include:

• Probiotics and prebiotics: The introduction of beneficial bacteria or substances that promote their growth to restore microbiome balance.
• Dietary interventions: Modifying diet to support a healthy microbiota and reduce inflammation.
• Fecal microbiota transplantation (FMT): Transferring microbiota from a healthy donor to restore a healthy gut ecosystem in patients with dysbiosis.
• Metabolite modulation: Developing drugs that mimic or block the action of microbial metabolites.

Further research, particularly utilizing multi-omics approaches that integrate data on the microbiome, metabolites, and gene expression, will be crucial for developing personalized and effective treatment strategies [5].

References

1. [1] Significant changes in the fecal bacteriobiota richness and diversity in patients with relapsing-remitting multiple sclerosis compared to healthy individuals. https://pubmed.ncbi.nlm.nih.gov/42640392/
2. [2] Intestinal microbiota-derived membrane vesicles and their role in chronic kidney disease. https://pubmed.ncbi.nlm.nih.gov/35787946/
3. [3] Multiomics Analysis Identifies Candidate Molecular, Microbiota, and Metabolite Features Associated with Acute Myocardial Infarction Combined with Chronic Renal Failure. https://pubmed.ncbi.nlm.nih.gov/42267897/
4. [4] Causal association between Parkinson disease, gut microbiota, and constipation: A Mendelian study. https://pubmed.ncbi.nlm.nih.gov/41261661/
5. [5] Integrated Metabolomics and Microbial Profiling in Patients with Irritable Bowel Syndrome. https://pubmed.ncbi.nlm.nih.gov/41581896/
6. [6] The Association Between Irritable Bowel Syndrome and Generalized Anxiety Disorder and Influencing Factors: A Mediation Mendelian Randomization Study. https://pubmed.ncbi.nlm.nih.gov/41676012/
7. [7] Protective Effects of Komagataeibacter rhaeticus SLAM-JS1B Derived Metabolites in High-Fat Diet-Induced Obesity. https://pubmed.ncbi.nlm.nih.gov/42532965/
8. [8] Associations between gut microbiota and Parkinson disease: A bidirectional Mendelian randomization analysis. https://pubmed.ncbi.nlm.nih.gov/37159496/

The information presented in this article is for informational purposes only and should not be used for self-diagnosis or self-treatment. Always consult a qualified medical professional for an accurate diagnosis and personalized treatment plan.